
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1054 | 978 | 1030 | 1170 | 1421 | 2090 |
Fund Return | 5.37% | -2.24% | 3.02% | 5.36% | 7.28% | 7.65% |
Place in category | 120 | 144 | 137 | 54 | 78 | 56 |
% in Category | 63 | 78 | 77 | 23 | 49 | 49 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Stock Market Ins Pls | 740.04B | 3.10 | 11.27 | - | ||
Vanguard 500 Index Admiral | 577.81B | 2.78 | 11.86 | 13.72 | ||
Vanguard Total Stock Market Admiral | 417.64B | 3.09 | 11.24 | 13.15 | ||
Vanguard 500 Index Institutional Se | 208.11B | 2.78 | 11.89 | - | ||
Vanguard Total Intl Stock Index Inv | 206.96B | 3.32 | 2.69 | 5.33 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity Select Health Care | 6.74B | 5.87 | 5.20 | 8.62 | ||
T. Rowe Price Health Sciences | 7.6B | 6.20 | 3.76 | 8.88 | ||
Vanguard Health Care Inv | 6.43B | 5.36 | 5.30 | 7.60 | ||
Fidelity Advisor Health Care A | 1.33B | 5.93 | 4.70 | 7.80 | ||
Fidelity Advisor Health Care C | 213.34M | 5.87 | 3.92 | 6.99 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.69 | 912.25 | -1.88% | |
UnitedHealth | US91324P1021 | 7.83 | 485.33 | +1.96% | |
AstraZeneca | GB0009895292 | 5.73 | 12,028.0 | -0.28% | |
Merck&Co | US58933Y1055 | 5.28 | 93.71 | +0.56% | |
Novo Nordisk B | DK0062498333 | 4.49 | 612.4 | -3.02% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Sell | Strong Sell |
Technical Indicators | Strong Buy | Sell | Strong Sell |
Summary | Strong Buy | Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review